![](/wp-content/uploads/2018/10/s88muvmRACfKSOYmpVeH.png)
$599
Sanofi Initiates New Toujeo vs. Tresiba T1DM CGM Study (inRange)
A CT.gov record has been observed for a new Sanofi-sponsored T1DM Ph4 Toujeo vs. Tresiba H2H non-inferiority trial utilizing CGM. Of note, the trial, called “inRange,” will evaluate time-in-range (TIR) as the primary outcome. Below, FENIX provides thoughts on this new trial in the context of the ongoing basal insulin saga between Sanofi and Novo Nordisk.